Phenobarbital

證據等級: L5

預測適應症: 10 個

Phenobarbital: From Seizure Disorders to Trigeminal Nerve Neoplasm (Low-Confidence Signal)

One-Sentence Summary

Phenobarbital is a long-established GABA-A receptor modulator whose registered original indication is not documented in this evidence pack (the drug is currently unregistered/not marketed in South Africa); its clinically established international use is in seizure/epilepsy management, as referenced in the underlying analysis notes. The TxGNN model’s top-ranked prediction is Trigeminal Nerve Neoplasm, but this is supported by 0 clinical trials and only 1 tangentially related publication, and the evidence pack’s own analysis explicitly flags this top prediction as likely model noise rather than a genuine signal. Evidence strength is minimal (L5), and the recommended decision is Hold.

Quick Overview

Item	Content
Original Indication	Not documented in the local regulatory record (no licenses on file); established international use is seizure/epilepsy management
Predicted New Indication	Trigeminal Nerve Neoplasm
TxGNN Prediction Score	99.96%
Evidence Level	L5
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for phenobarbital in this evidence pack. Based on the analysis notes accompanying the predictions, phenobarbital is a broad-spectrum positive allosteric modulator of the GABA-A chloride channel, with clinically established use across multiple seizure types. It has no known antineoplastic mechanism.

For the top-ranked candidate — trigeminal nerve neoplasm — the pack’s own repurposing rationale states this prediction is very likely a comorbidity-driven artifact: the single supporting publication is a 1997 case series on Sturge-Weber syndrome, in which phenobarbital was used to control the patient’s seizures, not to treat any tumour. There is no mechanistic pathway linking GABA-A modulation to tumour biology, and no oncology-specific trial or literature evidence exists for this pairing.

By contrast, several lower-ranked candidates in this same evidence pack (e.g., rank 2 “thinking/reflex seizures,” rank 3 “startle epilepsy,” and rank 9 “trigeminal neuralgia”) have a mechanistically coherent rationale rooted in phenobarbital’s genuine anticonvulsant/GABAergic activity and carry somewhat stronger (though still limited) literature support (L3–L4). These would be more defensible starting points than the rank-1 signal if this drug’s repurposing potential is pursued further.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9157801	1997	Case Series	Anales españoles de pediatría	Review of 14 Sturge-Weber syndrome cases; phenobarbital was used to manage the patients’ co-occurring seizures, not to treat the associated vascular/neural lesions — not direct evidence for a tumour indication

South Africa Market Information

Phenobarbital currently has no SAHPRA registrations on file (0 licenses; market status: Not Marketed). No product, dosage form, or approved indication text is available to summarize.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Note: the underlying evidence pack flags TFDA label warnings/contraindications as a Blocking-severity data gap (DG001) — this must be resolved before any safety pre-assessment (S1) can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale:

The top-ranked predicted indication (trigeminal nerve neoplasm) has L5 evidence — no clinical trials and a single, mechanistically unrelated case report — and is explicitly assessed by the underlying rationale as likely prediction noise from a comorbidity association rather than a real signal.
The drug is not currently registered or marketed in South Africa, and core safety data (warnings, contraindications, DDI) are entirely unavailable, blocking any safety evaluation.

To proceed, the following is needed:

Obtain the SAHPRA-approved (or TFDA source) Professional Information to resolve the blocking safety data gap (DG001)
Obtain confirmed mechanism-of-action documentation (DG002)
If repurposing is still of interest, redirect evaluation toward the mechanistically better-supported candidates in this same evidence pack (e.g., reflex/startle epilepsy subtypes or trigeminal neuralgia, both L3–L4) rather than the rank-1 signal
Assess the regulatory pathway for local registration, since phenobarbital is currently unmarketed in South Africa
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.